Payment overview · 2025
General Payments
$588.62
33 reported records · 10 companies
Healthcare provider profile · identity verified
Adrian P Padkowsky, M.D
Allopathic & Osteopathic Physicians|Internal Medicine · BAYONNE, NJ · NPI 1447559943
Verified facts
What the public records show
CMS Open Payments records show Adrian P Padkowsky, M.D received $588.62 in general payments during 2025 across 33 reported records.
AstraZeneca Pharmaceuticals LP accounted for 31.6% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 12 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Ozempic, Rybelsus.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported NEXIUM as an associated drug or biological on 464 records involving 299 distinct recipient NPIs. Public Medicare Part D data also shows 12 claims for Nexium by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 29 claims for Ozempic by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Rybelsus as an associated drug or biological on 161257 records involving 55409 distinct recipient NPIs. Public Medicare Part D data also shows 18 claims for Rybelsus by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $186.06 | 31.6% | 11 | 2025 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | Unresolved — no canonical attribution shown | $105.17 | 17.9% | 6 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $98.61 | 16.8% | 6 | 2025 |
| ABBVIE INC. | Unresolved — no canonical attribution shown | $50.97 | 8.7% | 3 | 2025 |
| BIOTRONIK NRO, Inc. | Unresolved — no canonical attribution shown | $49.03 | 8.3% | 2 | 2025 |
| Ardelyx, Inc. | Unresolved — no canonical attribution shown | $26.96 | 4.6% | 1 | 2025 |
| Incyte Corporation | Unresolved — no canonical attribution shown | $21.49 | 3.6% | 1 | 2025 |
| Janssen Pharmaceuticals, Inc | Unresolved — no canonical attribution shown | $21.36 | 3.6% | 1 | 2025 |
| Kowa Pharmaceuticals America, Inc. | Unresolved — no canonical attribution shown | $14.72 | 2.5% | 1 | 2025 |
| Vanda Pharmaceuticals Inc. | Unresolved — no canonical attribution shown | $14.25 | 2.4% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $588.62 | 33 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| CAPLYTA Normalized: caplyta |
Drug | ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | $105.17 | 6 | 2025 |
Source payment records
|
|||||
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $83.01 | 5 | 2025 |
Source payment records
|
|||||
| Rybelsus Normalized: rybelsus |
Drug | Novo Nordisk Inc | $83.01 | 5 | 2025 |
Source payment records
|
|||||
| VRAYLAR Normalized: vraylar |
Drug | ABBVIE INC. | $50.97 | 3 | 2025 |
Source payment records
|
|||||
| Prospera Normalized: prospera |
Device | BIOTRONIK NRO, Inc. | $49.03 | 2 | 2025 |
Source payment records
|
|||||
| IBSRELA Normalized: ibsrela |
Drug | Ardelyx, Inc. | $26.96 | 1 | 2025 |
Source payment records
|
|||||
| OPZELURA Normalized: opzelura |
Drug | Incyte Corporation | $21.49 | 1 | 2025 |
Source payment records
|
|||||
| SPRAVATO Normalized: spravato |
Drug | Janssen Pharmaceuticals, Inc | $21.36 | 1 | 2025 |
Source payment records
|
|||||
| Wegovy Normalized: wegovy |
Drug | Novo Nordisk Inc | $15.60 | 1 | 2025 |
Source payment records
|
|||||
| ZORYVE Normalized: zoryve |
Drug | Kowa Pharmaceuticals America, Inc. | $14.72 | 1 | 2025 |
Source payment records
|
|||||
| FANAPT Normalized: fanapt |
Drug | Vanda Pharmaceuticals Inc. | $14.25 | 1 | 2025 |
Source payment records
|
|||||
| HETLIOZ Normalized: hetlioz |
Drug | Vanda Pharmaceuticals Inc. | $14.25 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| Ozempic ozempic |
2025 | Ozempic | 2024 | 29 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| Rybelsus rybelsus |
2025 | Rybelsus | 2024 | 18 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | NEXIUM open payments reported associated product |
CMS Open Payments — General Payments 464 supporting records · 299 recipient NPIs · example record 1206134180 |
Nexium · 2024 Exact normalized brand match · 1 Part D row |
12 | suppressed by CMS |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
29 | suppressed by CMS |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Rybelsus open payments reported associated product |
CMS Open Payments — General Payments 161257 supporting records · 55409 recipient NPIs · example record 1188130076 |
Rybelsus · 2024 Exact normalized brand match · 1 Part D row |
18 | suppressed by CMS |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Alprazolam | Alprazolam | 489 | 92 |
| Atorvastatin Calcium | Atorvastatin Calcium | 306 | 88 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 280 | 79 |
| Amlodipine Besylate | Amlodipine Besylate | 271 | 79 |
| Lisinopril | Lisinopril | 206 | 61 |
| Levothyroxine Sodium | Levothyroxine Sodium | 203 | 49 |
| Metformin Hcl | Metformin Hcl | 184 | 57 |
| Zolpidem Tartrate | Zolpidem Tartrate | 176 | 36 |
| Pantoprazole Sodium | Pantoprazole Sodium | 164 | 55 |
| Metoprolol Succinate | Metoprolol Succinate | 141 | 38 |
| Losartan Potassium | Losartan Potassium | 122 | 32 |
| Metoprolol Tartrate | Metoprolol Tartrate | 120 | 27 |
| Prednisone | Prednisone | 119 | 79 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 114 | 29 |
| Simvastatin | Simvastatin | 114 | 21 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 104 | 30 |
| Ibuprofen | Ibuprofen | 103 | 52 |
| Tamsulosin Hcl | Tamsulosin Hcl | 103 | 25 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 100 | 38 |
| Eliquis | Apixaban | 96 | 22 |
| Fluticasone Propionate | Fluticasone Propionate | 95 | 39 |
| Furosemide | Furosemide | 91 | 31 |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 86 | 69 |
| Tramadol Hcl | Tramadol Hcl | 84 | 25 |
| Gabapentin | Gabapentin | 77 | 22 |
| Levofloxacin | Levofloxacin | 77 | 63 |
| Meloxicam | Meloxicam | 76 | 25 |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 74 | 66 |
| Omeprazole | Omeprazole | 74 | 17 |
| Clopidogrel | Clopidogrel Bisulfate | 73 | 19 |
| Sertraline Hcl | Sertraline Hcl | 68 | 24 |
| Hydrochlorothiazide | Hydrochlorothiazide | 66 | 20 |
| Azithromycin | Azithromycin | 62 | 57 |
| Glipizide | Glipizide | 59 | 18 |
| Lorazepam | Lorazepam | 56 | 14 |
| Oxycodone Hcl | Oxycodone Hcl | 54 | suppressed |
| Clotrimazole-Betamethasone | Clotrimazole/Betamethasone Dip | 53 | 28 |
| Diclofenac Sodium | Diclofenac Sodium | 52 | 14 |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 52 | 12 |
| Doxycycline Hyclate | Doxycycline Hyclate | 51 | 40 |
| Montelukast Sodium | Montelukast Sodium | 50 | 12 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 49 | 11 |
| Warfarin Sodium | Warfarin Sodium | 48 | suppressed |
| Paroxetine Hcl | Paroxetine Hcl | 47 | 12 |
| Levocetirizine Dihydrochloride | Levocetirizine Dihydrochloride | 43 | 11 |
| Mometasone Furoate | Mometasone Furoate | 42 | 28 |
| Pregabalin | Pregabalin | 37 | suppressed |
| Celecoxib | Celecoxib | 36 | suppressed |
| Escitalopram Oxalate | Escitalopram Oxalate | 35 | suppressed |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 34 | suppressed |
| Naproxen | Naproxen | 33 | 17 |
| Methylprednisolone | Methylprednisolone | 31 | 29 |
| Ondansetron Hcl | Ondansetron Hcl | 30 | 20 |
| Enalapril Maleate | Enalapril Maleate | 29 | suppressed |
| Mounjaro | Tirzepatide | 29 | suppressed |
| Ozempic | Semaglutide | 29 | suppressed |
| Temazepam | Temazepam | 29 | suppressed |
| Trulicity | Dulaglutide | 28 | suppressed |
| Meclizine Hcl | Meclizine Hcl | 27 | 18 |
| Allopurinol | Allopurinol | 26 | suppressed |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 26 | suppressed |
| Ropinirole Hcl | Ropinirole Hcl | 26 | suppressed |
| Tizanidine Hcl | Tizanidine Hcl | 25 | suppressed |
| Hydrocortisone | Hydrocortisone | 24 | suppressed |
| Bupropion Xl | Bupropion Hcl | 23 | suppressed |
| Carvedilol | Carvedilol | 23 | suppressed |
| Diazepam | Diazepam | 23 | suppressed |
| Digoxin | Digoxin | 23 | suppressed |
| Famotidine | Famotidine | 23 | suppressed |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 23 | 20 |
| Alendronate Sodium | Alendronate Sodium | 22 | suppressed |
| Pravastatin Sodium | Pravastatin Sodium | 20 | suppressed |
| Tobramycin-Dexamethasone | Tobramycin/Dexamethasone | 20 | 18 |
| Glimepiride | Glimepiride | 19 | suppressed |
| Januvia | Sitagliptin Phosphate | 19 | suppressed |
| Ramipril | Ramipril | 18 | suppressed |
| Rybelsus | Semaglutide | 18 | suppressed |
| Ssd | Silver Sulfadiazine | 18 | suppressed |
| Amiodarone Hcl | Amiodarone Hcl | 17 | suppressed |
| Ezetimibe-Simvastatin | Ezetimibe/Simvastatin | 17 | suppressed |
| Ibandronate Sodium | Ibandronate Sodium | 17 | suppressed |
| Omega-3 Acid Ethyl Esters | Omega-3 Acid Ethyl Esters | 17 | suppressed |
| Quetiapine Fumarate | Quetiapine Fumarate | 17 | suppressed |
| Valacyclovir | Valacyclovir Hcl | 17 | suppressed |
| Valsartan-Hydrochlorothiazide | Valsartan/Hydrochlorothiazide | 17 | suppressed |
| Bisoprolol-Hydrochlorothiazide | Bisoprolol/Hydrochlorothiazide | 16 | suppressed |
| Breo Ellipta | Fluticasone/Vilanterol | 16 | suppressed |
| Diphenoxylate-Atropine | Diphenoxylate Hcl/Atropine | 16 | 14 |
| Jardiance | Empagliflozin | 16 | suppressed |
| Memantine Hcl | Memantine Hcl | 16 | suppressed |
| Spironolactone | Spironolactone | 16 | suppressed |
| Atenolol | Atenolol | 15 | suppressed |
| Dextroamphetamine-Amphetamine | Dextroamphetamine/Amphetamine | 15 | suppressed |
| Dicyclomine Hcl | Dicyclomine Hcl | 15 | 11 |
| Ezetimibe | Ezetimibe | 15 | suppressed |
| Finasteride | Finasteride | 15 | suppressed |
| Nano 2nd Gen Pen Needle | Pen Needle, Diabetic | 15 | suppressed |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 15 | suppressed |
| Butalbital-Acetaminophen-Caffe | Butalb/Acetaminophen/Caffeine | 14 | suppressed |
| Cilostazol | Cilostazol | 14 | suppressed |
| Lovastatin | Lovastatin | 14 | suppressed |
| Ventolin Hfa | Albuterol Sulfate | 14 | suppressed |
| Calcitonin-Salmon | Calcitonin,salmon,synthetic | 13 | suppressed |
| Candesartan Cilexetil | Candesartan Cilexetil | 13 | suppressed |
| Myrbetriq | Mirabegron | 13 | suppressed |
| Calcitriol | Calcitriol | 12 | suppressed |
| Fenofibrate | Fenofibrate | 12 | suppressed |
| Metronidazole | Metronidazole | 12 | suppressed |
| Nexium | Esomeprazole Magnesium | 12 | suppressed |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 12 | suppressed |
| Ciclopirox | Ciclopirox | 11 | suppressed |
| Duloxetine Hcl | Duloxetine Hcl | 11 | suppressed |
| Eszopiclone | Eszopiclone | 11 | suppressed |
| Irbesartan | Irbesartan | 11 | suppressed |
| Metformin Hcl Er | Metformin Hcl | 11 | suppressed |
| Midodrine Hcl | Midodrine Hcl | 11 | suppressed |
| Phenytoin Sodium Extended | Phenytoin Sodium Extended | 11 | suppressed |
| Propranolol Hcl | Propranolol Hcl | 11 | suppressed |
| Tresiba Flextouch U-200 | Insulin Degludec | 11 | suppressed |
| Vyvanse | Lisdexamfetamine Dimesylate | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $588.62 · 33 records | AstraZeneca Pharmaceuticals LP | CAPLYTA, FANAPT, HETLIOZ, IBSRELA, OPZELURA, Ozempic, Prospera, Rybelsus, SPRAVATO, VRAYLAR, Wegovy, ZORYVE | 3 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Ozempic play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with AstraZeneca Pharmaceuticals LP?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error